A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma (NCT04973605)

🧪 Interventions in This Study

• Sonrotoclax (DRUG)
• Dexamethasone (DRUG)
• Carfilzomib (DRUG)
• Daratumumab (DRUG)
• Pomalidomide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (82 Sites)

Showing the first 25 of 82 sites.

• University of Alabama At Birmingham Hospital — Birmingham, Alabama
• City of Hope National Medical Center — Duarte, California
• City of Hope Irvine Lennar — Irvine, California
• University of Miami — Miami, Florida
• Emory University Winship Cancer Center — Atlanta, Georgia
• University of Chicago Medical Center — Chicago, Illinois
• Massachusetts General Hospital — Boston, Massachusetts
• Washington University School of Medicine — St Louis, Missouri
• Hackensack University Medical Center — Hackensack, New Jersey
• Weill Cornell Medical College Newyork Presbyterian Hospital — New York, New York
• Memorial Sloan Kettering Cancer Center Mskcc — New York, New York
• The James Cancer Hospital and Solove Research Institute At Ohio State University — Columbus, Ohio
• Huntsman Cancer Institute — Salt Lake City, Utah
• University of Washington — Seattle, Washington
• University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
• Medical College of Wisconsin — Milwaukee, Wisconsin
• Canberra Hospital — Garran, Australian Capital Territory
• Nepean Hospital — Kingswood, New South Wales
• Monash Health — Clayton, Victoria
• St Vincents Hospital Melbourne — Fitzroy, Victoria
• The Alfred Hospital — Melbourne, Victoria
• Royal Perth Hospital — Perth, Western Australia
• Hospital Sirio Libanes Brasilia — Brasília,
• Instituto Dor de Pesquisa E Ensino Distrito Federal — Brasília,
• Centro Gaucho Integrado de Oncologia Hospital Mae de Deus — Porto Alegre,

📞 Contact the Study Coordinator

Phone: (877) 828-5568

Email: clinicaltrials@beonemed.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Relapsed/Refractory Multiple Myeloma

• A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets — Stanford, California
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma — Little Rock, Arkansas
• Cevostamab Following CAR T Cell Therapy for RRMM — Philadelphia, Pennsylvania
• A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma — Clayton, North Carolina
• CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma — Birmingham, Alabama

Explore by condition: All Relapsed/Refractory Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.